NEW YORK, Oct 20 – Just two days after its birth as a spin off from Theratechnologies, microbial genomics company Ecopia BioSciences said Friday it had signed a microbial sequencing deal with Kosan BioSciences.

Under the agreement, Ecopia will apply its genomics platform in order to discover the genes of a particular microorganism that direct the synthesis of an undisclosed small molecule, which is of interest to Kosan.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.